DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer

被引:76
作者
Velic, Denis [1 ,2 ,3 ]
Couturier, Anthony M. [1 ,2 ]
Ferreira, Maria Tedim [2 ,4 ]
Rodrigue, Amelie [1 ,2 ]
Poirier, Guy G. [2 ,4 ]
Fleury, Fabrice [3 ]
Masson, Jean-Yves [1 ,2 ,4 ]
机构
[1] CHU Quebec, Res Ctr, Genome Stabil Lab, Oncol Axis, HDQ Pavil,9 McMahon, Quebec City, PQ G1R 2J6, Canada
[2] Univ Laval, Ctr Rech Canc, Dept Mol Biol Med Biochem & Pathol, Quebec City, PQ G1V 0A6, Canada
[3] Univ Nantes, CNRS, DNA Repair Regulat Team, UFIP,UMR 6286, F-44322 Nantes, France
[4] CHU Quebec, Res Ctr, Oncol Axis, Quebec City, PQ G1V 4G2, Canada
来源
BIOMOLECULES | 2015年 / 5卷 / 04期
基金
加拿大健康研究院;
关键词
DNA repair; inhibitors; ATM; ATR; CHK1; CHK2; MRE11; RAD51; PARP;
D O I
10.3390/biom5043204
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
For decades, radiotherapy and chemotherapy were the two only approaches exploiting DNA repair processes to fight against cancer. Nowadays, cancer therapeutics can be a major challenge when it comes to seeking personalized targeted medicine that is both effective and selective to the malignancy. Over the last decade, the discovery of new targeted therapies against DNA damage signalling and repair has offered the possibility of therapeutic improvements in oncology. In this review, we summarize the current knowledge of DNA damage signalling and repair inhibitors, their molecular and cellular effects, and future therapeutic use.
引用
收藏
页码:3204 / 3259
页数:56
相关论文
共 303 条
  • [1] Cell cycle checkpoint signaling through the ATM and ATR kinases
    Abraham, RT
    [J]. GENES & DEVELOPMENT, 2001, 15 (17) : 2177 - 2196
  • [2] The Chk2 protein kinase
    Ahn, J
    Urist, M
    Prives, C
    [J]. DNA REPAIR, 2004, 3 (8-9) : 1039 - 1047
  • [3] The N-terminal domain of the human Rad51 protein binds DNA: Structure and a DNA binding surface as revealed by NMR
    Aihara, H
    Ito, Y
    Kurumizaka, H
    Yokoyama, S
    Shibata, T
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1999, 290 (02) : 495 - 504
  • [4] AJIMURA M, 1993, GENETICS, V133, P51
  • [5] A small-molecule inhibitor of RAD51 reduces homologous recombination and sensitizes multiple myeloma cells to doxorubicin
    Alagpulinsa, David A.
    Ayyadevare, Srinivas
    Reis, Robert Joseph Shmookler
    [J]. FRONTIERS IN ONCOLOGY, 2014, 4
  • [6] Allen C, 2003, MOL CANCER RES, V1, P913
  • [7] The PARP superfamily
    Amé, JC
    Spenlehauer, C
    de Murcia, G
    [J]. BIOESSAYS, 2004, 26 (08) : 882 - 893
  • [8] CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors
    Anderson, Victoria E.
    Walton, Michael I.
    Eve, Paul D.
    Boxall, Katherine J.
    Antoni, Laurent
    Caldwell, John J.
    Aherne, Wynne
    Pearl, Laurence H.
    Oliver, Antony W.
    Collins, Ian
    Garrett, Michelle D.
    [J]. CANCER RESEARCH, 2011, 71 (02) : 463 - 472
  • [9] Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles
    Arienti, KL
    Brunmark, A
    Axe, FU
    McClure, K
    Lee, A
    Blevitt, J
    Neff, DK
    Huang, LM
    Crawford, S
    Pandit, CR
    Karlsson, L
    Breitenbucher, JG
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) : 1873 - 1885
  • [10] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    Audeh, M. William
    Carmichael, James
    Penson, Richard T.
    Friedlander, Michael
    Powell, Bethan
    Bell-McGuinn, Katherine M.
    Scott, Clare
    Weitzel, Jeffrey N.
    Oaknin, Ana
    Loman, Niklas
    Lu, Karen
    Schmutzler, Rita K.
    Matulonis, Ursula
    Wickens, Mark
    Tutt, Andrew
    [J]. LANCET, 2010, 376 (9737) : 245 - 251